By Rishab Shaju and Ateev Bhandari (Reuters) -Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares ...

HeartFlow’s current products are HeartFlow Plaque analysis, which aims to provide clinicians with the ability to more ...

Heartflow, Inc. has announced that UnitedHealthcare will cover its Heartflow Plaque Analysis across all business lines, making it the first insurer to align its policies with new guidelines from ...

Heartflow (NASDAQ: HTFL) stock surges ~50% as the company focused on AI-driven tools for the diagnosis of heart diseases make ...

HeartFlow’s AI-based CAD platform targets a large market with strong adoption, but IPO valuation and risks warrant caution.

Shares of Heartflow opened at $28 on Friday, jumping over 47% above the initial public offering price of $19 per share in their Nasdaq debut. This opening price valued the medical technology company ...

Heartflow, Inc. (NASDAQ:HTFL) successfully raised $316.7 million from its IPO, having sold 16.67 million shares at a price of ...

Heartflow announced today that it closed its upsized initial public offering (IPO) with proceeds totaling approximately $364.2 million.

Medical technology firm Heartflow said on Thursday it had raised $316.7 million in its U.S. initial public offering, setting the stage for its Nasdaq debut in another test of investor appetite for ...

The company, which sells software for creating 3D heart models, plans to offer 12.5 million shares at a range of $15 to $17 ...

Heartflow, backed by private investment firm Bain Capital, said on Wednesday it was targeting a valuation of up to $1.46 ...